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Vascular network formation is essential for tissue 
growth during development. When we reach 
adulthood, the vascular endothelium becomes 
quiescent.  However,  under  disease  conditions, 
this delicate balance is disturbed, and endothe-
lium is reactivated. Knowing how pathological 
angiogenesis occurs has important implications 
in  controlling  the  growth  and  progression  of 
diseases such as cancer.
The vascular system shares several striking 
anatomical similarities with the nervous system. 
They both consist of a highly complex and pre-
cisely branched network. They often run paral-
lel and intimately interact, suggesting a common 
mechanism regulating the formation of both 
networks (Mukouyama et al., 2002; Weinstein,   
2005;  Carmeliet  and Tessier-Lavigne,  2005; 
Jones  and  Li,  2007).  Indeed,  findings  have 
shown that angiogenic factors, such as VEGF, 
also regulate neuronal growth and development 
(Oosthuyse et al., 2001; Jin et al., 2002). Recip-
rocally, neuropilin, a receptor for semaphorin 
that controls neuronal growth, is also expressed 
in vascular endothelium and regulates vascular 
development (Lee et al., 2002).
-Catenin is a neuronal protein containing 
10 Armadillo repeats. It belongs to the p120 
family of proteins (Hatzfeld, 2005). The major 
functions of the p120 protein family include 
stabilization of cadherins by binding to a highly 
conserved sequence in the juxtamembrane re-
gion, as well as regulating Rho GTPase activity 
and cell motility (Reynolds, 2007). -Catenin 
is localized to the postsynaptic adherens junc-
tion in neuronal cells, collaborates with Rho 
GTPases to set a balance between neurite elon-
gation and branching, and induces dendritic 
protrusions in neurons (Martinez et al., 2003). 
Genetic deletion of -catenin in mice results in 
severe deficits in several types of memory and 
synaptic plasticity (Israely et al., 2004), which is 
consistent with the neuronal phenotype.
In this study, we demonstrate haploinsuffi-
ciency of -catenin specifically in pathological 
angiogenesis. -Catenin is expressed in vascular 
endothelium. It regulates endothelial cell motility 
and angiogenesis in tumors and wound heal-
ing in a gene dosage–sensitive manner. In addi-
tion, inflammatory cytokines up-regulate the 
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Vascular and neuronal networks share a similar branching morphology, and emerging evi-
dence implicates common mechanisms in the formation of both systems. -Catenin is 
considered a neuronal catenin regulating neuron cell–cell adhesion and cell motility. Here, 
we report expression of -catenin in vascular endothelium, and show that deletion of only 
one allele of -catenin is sufficient to impair endothelial cell motility and vascular assem-
bly in vitro and pathological angiogenesis in vivo, thereby inhibiting tumor growth and 
wound healing. In contrast, deletion of one or both allele of -catenin had no effects on 
hormone-induced physiological angiogenesis in the uterus. Molecular analysis confirmed a 
gene dosage effect of -catenin on Rho GTPase activity. Moreover, we show that inflam-
matory cytokines, but not angiogenic factors, regulate -catenin expression, and the levels 
of -catenin positively correlate to human lung cancers. Collectively, our data suggest that 
inflammation, commonly associated with disease conditions, induces -catenin expression 
that specifically regulates pathological, and not physiological, angiogenesis. Because only 
pathological angiogenesis is sensitive to decreased levels of -catenin, this may provide a 
good target for antiangiogenic therapy.
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tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons.
org/licenses/by-nc-sa/3.0/).
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tent with the function of -catenin in cell–cell junctions and 
cell motility.
Additionally, we analyzed expression of -catenin in tissue 
samples. A double staining using antibodies against -catenin 
and CD31, a marker for endothelium, confirmed expression 
of the gene in vascular endothelium in skin (Fig. 1 C) and tu-
mor samples (Fig. S1). The -catenin antibody failed to de-
tect any signal in tissues harvested from -catenin–null mice 
(Fig. 1 C and Fig. S1). Collectively, these findings for the first   
time demonstrate the presence of neuronal -catenin in vas-
cular endothelium. Considering the role of -catenin in cell–
cell junction and cell motility, these data suggest a role for   
-catenin in angiogenesis.
-Catenin regulates endothelial cell motility  
and vascular network formation in a gene dosage–
dependent manner in vitro
To test the function of -catenin in angiogenesis, we used 
-catenin–null mice. Besides deficiency in memory and syn-
aptic plasticity, the null mice are healthy, fertile, and they grow 
normally (Israely et al., 2004). We isolated and purified micro-
vascular endothelial cells from lungs of wild-type, hetero-
zygous, and -catenin knockout mice. We achieved >95% purity 
(CD31 positive) in each group of cells (Fig. 2 A). Reduction   
and total absence of -catenin expression in heterozygous- 
and homozygous-null cells, respectively, were confirmed by 
Western blot (Fig. 2 B). Next, we analyzed the role of  -catenin 
in angiogenesis by measuring endothelial cell motility, vascular 
sprouting in a 3-D Matrigel assay, and cell proliferation. We 
found that a total deletion of -catenin significantly impaired 
cell motility and vascular structure formation, but deletion of 
-catenin had no effects on cell proliferation (Fig. 2, C–E). 
Surprisingly, we detected -catenin haploinsufficiency in   
regulating  angiogenesis. There  is  a  significant  reduction  of   
cell motility and vascular structure formation when deleting 
only one allele of the gene (Fig. 2, C–E). The levels of angio-
genic function in heterozygous cells are similar to the ones 
from homozygous-null cells. These findings reveal new func-
tions of -catenin in angiogenesis that act in a gene dosage–
dependent manner.
To verify these findings, we also applied short hairpin 
RNA (shRNA) to specifically knockdown -catenin in hu-
man endothelial cells. HUVECs were treated with shRNA 
for 24 h, and expression levels of -catenin were verified   
using  Western  blot.  We  achieved  75%  knockdown  of   
-catenin expression in endothelial cells compared with con-
trols (Fig. S2 A). Consistently, knockdown of -catenin in en-
dothelial cells significantly impaired cell motility (Fig. S2 B) 
and vascular tubule formation in 3-D Matrigel (Fig. S2 C), 
but had no effect on cell proliferation (not depicted). Recip-
rocally, overexpression of -catenin in endothelial cells using 
an expression vector (Fig. S2 D) significantly increased cell   
motility (Fig. S2 E) and vascular network formation in Matrigel   
(Fig. S2 F). Collectively, these data support a role of -catenin 
in angiogenesis via regulation of endothelial cell motility and 
vascular network assembly.
gene expression and the levels of -catenin are elevated in 
human lung cancers compared with surrounding normal tis-
sues, which is consistent with its role in pathological angiogen-
esis, as inflammation is closely associated with cancer.
RESULTS
Neuronal -catenin is expressed in vascular endothelium
Based on the observation that the vascular and neuronal sys-
tems share a similar treelike branched structure and certain 
common mediators (Jones and Li, 2007), we postulate that   
-catenin, a neuronal catenin, may have a role in vascular 
endothelium. To test this hypothesis, we examined -catenin 
expression in human endothelial cells. We included neuronal 
cells (HT-22 and U251MG), as well as epithelial cells (293) 
and leukocytes (U937 and THP-1). In addition to neuronal 
cell lines, -catenin expression was clearly demonstrated in 
large (human umbilical vein endothelial cell [HUVEC]) and 
small (human microvascular endothelial cell [HMEC]) vascu-
lar endothelial cells, but not in any of the other cell types 
tested (Fig. 1 A). Immunofluorescent staining in cultured 
monolayer endothelial cells demonstrated -catenin expres-
sion at cell–cell junctions and intracellularly (Fig. 1 B), consis-
Figure 1.  -Catenin is expressed in vascular endothelium.  
(A) Protein lysates collected from neuronal cells (HT-22 and U251 MG), 
endothelial cells (ECs; HUVEC and HMEC), epithelial cells (293), and leu-
kocytes (THP-1 and U937) were subjected to Western blot analysis and 
probed with a -catenin–specific antibody. (B) -tubulin was used as a 
loading control. Immunofluorescent staining for -catenin was per-
formed in cultured HUVECs. (C) Mouse skin tissue sections from wild-
type and -catenin–null mice were analyzed by immunofluorescent 
double staining using antibodies against CD31 for endothelium, and  
-catenin. Nuclei were stained with DAPI. 4003 magnification. Each 
experiment was repeated three times, and representative images were 
shown. Bar, 200 µm.JEM VOL. 207, January 18, 2010 
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significant  reduction  of  activation  of  these  two  Rho   
GTPases. All together, these results indicate that -catenin 
mediates Rac1 and Cdc42 activation in endothelial cells 
likely through Vav1.
Haploinsufficiency of -catenin impairs pathological 
angiogenesis in tumor growth and wound healing
As tumor growth depends on tumor angiogenesis, we there-
fore investigated the function of -catenin in tumor angio-
genesis. Murine 3LL tumor cells were implanted in syngeneic 
-catenin  homozygous-null,  heterozygous-null,  and  wild-
type littermates. Tumor growth was measured over time. 
Consistent with the in vitro data on gene dosage of -catenin 
in angiogenesis, we observed a significant retardation in tu-
mor growth in homozygous-null mice, as well as in hetero-
zygous-null mice, compared with wild-type controls (Fig. 5 A), 
which correlates to a reduced tumor vascular density in tu-
mors harvested from these null mice (Fig. 5 B and Fig. S4). 
No significant difference in tumor growth and tumor vascu-
lar density between the heterozygous- and homozygous-null 
mice was observed, consistent with the observations of endo-
thelial cell motility and vascular structure formation between 
these two groups. The experiment was repeated twice, and 
consistent results were achieved.
To further establish the role of -catenin in angiogenesis 
in vivo, we also tested it in wound healing using a skin biopsy 
puncture model. Consistent with the results from tumor 
-Catenin inhibits RhoA activity, but enhances Rac1  
and Cdc42 activity, likely through interaction with Vav1  
in endothelial cells
The p120 family of proteins, including -catenin, is known 
to regulate cell motility through Rho GTPases (Noren et al., 
2000; Grosheva et al., 2001). We therefore determined the 
effects of -catenin on Rho GTPase activation in endothelial 
cells isolated from wild-type, heterozygous-null, and homo-
zygous-null mice. Consistent with the observation of haplo-
insufficiency of -catenin in angiogenic functions, we found 
that reduction or deletion of the -catenin gene significantly 
inhibited activation of Rac1 and Cdc42, but enhanced RhoA   
activation (Fig. 3), Similar observations were made with   
-catenin knockdown in human endothelial cells, and the 
opposite was observed with overexpression of -catenin   
(Fig. S3). These findings provide molecular mechanism for 
haploinsufficiency of -catenin in endothelial cell motility 
and angiogenesis.
Vav1 is a guanine nucleotide exchange factor for Rho 
GTPases.  Vav1  is  specifically  expressed  in  hematopoietic   
cells (Bustelo, 2000; Tybulewicz et al., 2003), as well as in 
endothelial cells (Georgiades et al., 2002). Using immuno-
precipitation, we demonstrated an association of Vav1 with 
-catenin  in  cultured  endothelial  cells  (Fig.  4,  A  and  B).   
Furthermore, overexpression of Vav1 in endothelial cells sig-
nificantly increased Cdc42 and Rac1 activation (Fig. 4, C–F). 
Reciprocally, knockdown of  Vav1  by shRNA  led  to a   
Figure 2.  -Catenin regulates endothelial cell motility and vascular tubule formation in vitro in a gene dosage–sensitive manner. (A) Micro-
vascular endothelial cells were isolated and pooled from lungs (5 mice per group) of wild-type littermates, -catenin heterozygous-null, and homo-
zygous-null mice. The endothelial cells were sorted with a CD31 antibody with a FACStarPlus flow cytometer. The percentage of CD31 positive cells was 
indicated in each graph. (B) The levels of -catenin in wild-type, -catenin+/, and -catenin/ endothelial cells were evaluated in cell lysates by Western 
blot. Endothelial cell migration and vascular tubule formation were measured in Transwell assay or Matrigel assay, respectively. (C) Migrated cells were 
counted after a 5-h incubation in 10 randomly selected high-power fields under microscopy. The data were collected from three independent experi-
ments. Mean and SE were plotted. *, P < 0.01. (D) Vascular tubule formation was measured 18 h after cell plating. Vascular cross points were counted 
from 10 randomly selected high-power fields under microscopy. The data were collected from three independent experiments. *, P < 0.01. (E) Cell prolif-
eration was measured by BrdU incorporation. The experiment was done in duplicate and repeated three times.80 -Catenin regulates pathological angiogenesis | DeBusk et al.
with the phenotype that -catenin–null mice are fertile   
and produce a similar number of offspring as the wild-type   
littermates. Collectively, our data reveal a specific role of   
-catenin in pathological angiogenesis in a gene dosage   
dependent manner. These notable observations resulting 
from heterozygous deletion of -catenin demonstrate the 
sensitive nature of pathological angiogenesis to subtle changes 
of -catenin levels.
Inflammatory cytokines induce the expression of -catenin 
in vascular endothelial cells, and -catenin levels  
are elevated in human lung cancer
To investigate the molecular mechanisms linking -catenin 
specifically to pathological angiogenesis, we studied gene ex-
pression. We found that inflammatory cytokines, including 
TNF and IL-1, increased -catenin expression in a dose-
  dependent manner in vascular endothelial cells (Fig. 7, A and 
B), and that gene induction depended on NF-B, a key reg-
ulator of inflammation. Neutralization of NF-B activation 
using a mutant IB construct completely blocked inflam-
matory cytokine-induced -catenin expression in endothelial 
cells (Fig. 7, C and D). In contrast, angiogenic factors such as 
studies, there was a significant impairment of angiogenesis 
and wound closure in homozygous- and heterozygous-null 
mice compared with control mice, and indifference between 
heterozygous- and homozygous-null groups in these mea-
surements (Fig. 5, C and D). These findings further confirmed 
a gene dosage effect of -catenin in angiogenesis. Deletion of 
one copy of -catenin is sufficient to impair pathological an-
giogenesis, and thus contributes to impaired tumor growth 
and wound healing in vivo. The experiment was repeated 
once, and consistent results were observed.
Remarkably, an analysis of the function of -catenin in 
physiological angiogenesis in uterus, as it occurs during the 
female  reproduction  cycle,  demonstrated  no  difference  in 
hormonally induced physiological angiogenesis among dif-
ferent groups (Fig. 6). The experiment was repeated once 
and similar results were observed. This result is consistent   
Figure 3.  -Catenin regulates Rho GTPase activity in a gene dos-
age sensitive manner. Microvascular endothelial cells isolated from 
wild-type littermates, -catenin heterozygous-null, and homozygous-null 
mice were analyzed for Rho GTPase activity. Activation of Rac1 and Cdc42 
was measured by PAK1-efficient pull-down assays. Precipitated activated 
Rac1 (A and B) or Cdc42 (C and D) and each total protein from cell lysate 
were analyzed by Western blot with specific antibody. RhoA activation  
was pulled down with Rhotekin-agarose beads, analyzed by Western  
blot, and probed with a RhoA-specific antibody (E and F). *, P < 0.001.  
Each experiment was repeated three times, and representative images  
were shown.
Figure 4.  Vav1 interacts with -catenin and activates Cdc42 and 
Rac1. HUVECs were transfected with either an expression vector for con-
trol GFP or -catenin, or transfected with control shRNA or -catenin 
shRNA for 48 h. (A) Cell lysate was immunoprecipitated with antibody 
against Vav1 or control beads (none), and subjected to Western blot analy-
sis with antibody against -catenin. Equal amount of cell lysate (lysate) 
was used as a loading control. (B) Cell lysate was also immunoprecipitated 
with antibody against -catenin or control beads (none) and subjected to 
Western blot analysis for Vav1. Equal amount of lysate (lysate) was used 
as a loading control. Cell lysates were analyzed for Cdc42 (C) and Rac1 (E) 
activation using PAK1-efficient pull-down assay. Precipitated and total 
protein was analyzed by Western blot. The levels of activated Cdc42 were 
compared with total levels of Cdc42 (D), and activated Rac1 to total levels 
of Rac1 (F). *, P < 0.05 and **, P < 0.01, compared with corresponding 
control. Each experiment was repeated three times, and representative 
images were shown.JEM VOL. 207, January 18, 2010 
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DISCUSSION
It  is  apparent  that  molecular  mechanisms  underlying  the   
development of the nervous system have been co-opted by 
the  vasculature.  Certain  neuronal  guidance  molecules  also 
regulate angiogenesis and vascular patterning (Mukouyama   
et al., 2002; Carmeliet and Tessier-Lavigne, 2005; Weinstein, 
2005; Jones and Li, 2007). In this study, we demonstrate that 
a neuronal catenin of the p120 family, -catenin, is also ex-
pressed in vascular endothelium. -Catenin regulates endothelial 
cell motility and vascular network assembly via modulation of 
Rho GTPase activity. Most importantly, we observed a gene 
dosage effect and haploinsufficiency of -catenin in patholog-
ical angiogenesis. Deletion of one allele of -catenin is suffi-
cient to inhibit angiogenesis in tumor progression and wound 
healing, but has no effect on hormone-induced physiological 
angiogenesis in the uterus. Collectively, this study identifies a 
novel  function  of  -catenin  in  vascular  biology  associated 
with disease conditions.
This work is the first to document -catenin expression 
in the vascular endothelium. This expression pattern is not 
surprising, as there have been several proteins that are ex-
pressed in both neural and endothelial tissues, and regulate 
the branching morphogenesis of both systems. These mole-
cules include members of the Ephrin-Eph family, Slit/Robo 
families, and the Netrins and Semaphorins (Eichmann et al., 
2005). -Catenin is yet another protein that plays a role   
in both tissue types. Consistent with the role of -catenin   
in  neural  cell  motility  (Lu  et  al.,  1999;  Martinez  et  al.,   
2003; Kosik et al., 2005), we show here that -catenin 
basic fibroblast growth factor, vascular endothelial growth 
factor, and angiopoietin 1 failed to induce -catenin expres-
sion (Fig. 7, E–G).
A major difference separating physiological angiogenesis in 
normal  growth  from  pathological  angiogenesis  in  diseases  is   
inflammation. Inflammatory cytokines often possess proangio-
genic properties and activate angiogenic genes, as in our ob-
servation in -catenin in angiogenesis in this study. Because 
inflammation is elevated in cancer tissues and inflammatory cy-
tokines up-regulate -catenin expression, we examined -catenin 
expression  in  tumor  tissues.  Consistently,  elevated  levels  of   
-catenin were clearly observed in human lung cancer samples 
compared  with  corresponding  adjacent  normal  lung  tissues   
(Fig. 7 H). These findings further support our assessment and link 
-catenin to pathological angiogenesis through inflammation.
Figure 5.  Genetic deletion of -catenin in mice impairs pathologi-
cal angiogenesis in a dose-dependent manner. 3LL tumor cells were 
injected subcutaneously into sex- and age-matched syngeneic -catenin 
homozygous-null, heterozygous-null, and wild-type littermates. (A) Tumor 
growth was measured by caliper for 15 d, and tumor volume was calcu-
lated and plotted (n = 10 mice/group; *, P < 0.001). (B) Tumor tissue sec-
tions from each group were analyzed by CD31 immunofluorescent 
staining, and CD31 positive vessels were counted from 10 randomly se-
lected high-power fields under microscopy. Mean and SE were plotted.  
*, P < 0.05. (C) 6-mm biopsy punches were made in wild-type littermates,  
-catenin heterozygous-null, and -catenin homozygous-null mice. 
Wound size was measured daily. The percent changes of wound size over 
the original size were plotted (n = 7 mice/group; *, P < 0.01). (D) The  
vascular density measurement by vWF staining was performed in  
wounded tissues on day 3. Mean and SE were plotted. *, P < 0.01.
Figure 6.  Deletion of -catenin in mice has no effect on hor-
mone-induced angiogenesis in uterus. Female mice were super-
ovulated, and the uteruses were harvested from wild-type littermates (A), 
heterozygous-null (B), and homozygous-null -catenin (C) mice. Hema-
toxylin and eosin staining was performed on tissue sections (A–C) for 
histological analysis. Arrows point to blood vessels. The tissue sections 
were also probed with a vWF antibody for vascular density. Positive vessels 
were counted from 10 randomly selected high-power fields under micros-
copy. Mean and SE were plotted (D). Bar, 200 µm.82 -Catenin regulates pathological angiogenesis | DeBusk et al.
function in regulation of Rho GTPase activation. On the 
one hand, it activates Rac and Cdc42. On the other hand, it 
inhibits RhoA activation. Consistent with the findings in 
p120, we found that -catenin activates Rac1 and Cdc42, 
and inhibits RhoA activation in endothelial cells. In search-
ing for GEFs that might interact with -catenin in endothe-
lial cells, we found that Vav1, the major isoform of Vav family 
proteins in endothelial cells, associates with -catenin. Over-
expression  of  Vav1  increases  Rac1  and  Cdc42  activities, 
whereas knockdown of Vav1 decreases these activities. These 
data imply that -catenin activates Rac1 and Cdc42, likely 
through recruitment of Vav1 in endothelial cells. Likewise, a 
study links Vav2 to p120 in Rac and Cdc42 activation in epi-
thelial and fibroblast cells (Noren et al., 2000). Although 
p120 can clearly act in a GDI-like fashion to directly in-
hibit RhoA, new evidence suggests that p120 may also   
inhibit RhoA via recruitment of p190RhoGAP to cadherin 
(Wildenberg et al., 2006; Reynolds, 2007). It is conceivable 
to believe a similar mechanism of -catenin in suppression of 
RhoA activation in endothelial cells.
One of the major findings from the study is haploinsuffi-
ciency of -catenin in endothelial cell motility and angio-
genesis. Deletion of one allele of the gene significantly inhibits 
angiogenesis in tumors and wound healing. This gene dosage 
effect is well supported by our in vitro data. A reduction of   
-catenin  levels  results  in  a  significant  inhibition  of  Rho   
GTPase activity, and impairs endothelial cell motility and 
vascular structure assembly in vitro. There is no difference in 
the context of Rho GTPase activity and angiogenic functions 
between heterozygous- and homozygous-null cells. Impor-
tantly, the haploinsufficiency of -catenin is also supported 
by genetic evidence in patients with Cri-du-chat syndrome. 
These patients often lack one copy of the -catenin gene be-
cause of a deletion of regions of the short arm of chromo-
some 5. They show a profound delay in development and 
neuronal defects, as well as congenital heart defects, including 
ventricular septal defects in 15–20% of patients (Hills et al., 
2006). As endothelial motility is an essential step in cardio-
vascular development, our findings may provide molecular 
evidence linking haploinsufficiency of -catenin with con-
genital heart defects associated with Cri-du-chat syndrome. 
Collectively, our findings reflect the sensitive nature of patho-
logical angiogenesis to subtle changes of -catenin levels. 
Targeting this protein may offer an effective approach for 
controlling angiogenic diseases.
Another  important  finding  from  this  work  is  linking   
-catenin specifically to pathological angiogenesis. Deletion 
or reduction of the gene inhibited angiogenesis associated 
with tumor progression and skin wound healing, as both pro-
cesses are tightly linked to inflammation. In contrast, there is 
no difference in hormone-induced physiological angiogene-
sis in the uterus among different groups. Angiogenesis is the 
body’s response to tissue growth and regeneration, including 
normal growth during development and growth in disease 
conditions. One of the major differences between pathological 
angiogenesis and physiological angiogenesis is inflammation 
regulates endothelial cell motility, vascular assembly, and 
angiogenesis.
Rho family GTPases, including RhoA, Rac, and Cdc42, 
are key mediators of cytoskeleton dynamics and cell motility. 
There is strong evidence that p120 and -catenin regulate 
cell motility, at least in part, through modulation of Rho 
GTPase  activation  (Kosik  et  al.,  2005;  Reynolds,  2007). 
p120, the prototype member of the family, exhibits opposite 
Figure 7.  Inflammatory cytokines induce the expression of  
-catenin through NF-B in vascular endothelial cells. HUVECs were 
treated with increasing doses of either IL-1 (A) or TNF (B) for 24 h, and 
cell lysate was subjected to Western blotting for -catenin and -tubulin 
expression. HUVECs were infected with adenoviral vectors expressing 
either GFP or a mutant IB for 24 h, followed by stimulation with re-
combinant IL-1 (C) or TNF (D) at 3 ng/ml for another 24 h. -Catenin ex-
pression was evaluated by Western blot. HUVECs were treated with 
increasing doses of either recombinant bFGF (E) or VEGF (F) for 24 h, and 
cell lysate was subjected to Western blotting for -catenin expression.  
(G) HUVECs were infected with adenoviral vector expressing GFP or Ang1 
for 48 h, respectively. -Catenin expression was detected by Western blot. 
(H) Human lung tumor tissues (T) and adjacent normal lung tissues (N) 
from biopsies were subjected to Western blotting with -catenin or  
-tubulin antibodies (n = 3 pairs).JEM VOL. 207, January 18, 2010 
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experiment, tumor tissues were harvested, freshly frozen, and embedded in 
OCT. 7-µm sections were cut and subjected to immunohistochemistry. The 
tumor study was repeated twice with seven mice per group.
Two wounds were made on the back of each mouse using a 6-mm skin 
biopsy punch. The wound dimensions were measured daily and the wound 
area was calculated as (long radius)(short radius). The percent change was 
calculated as (initial wound area)  (current wound area)/(initial wound 
area). The experiment was repeated once with seven mice per group.
4-5-wk-old female mice were treated with gonadotropin from pregnant 
mare serum (Sigma-Aldrich) for 48 h, followed by human chorionic gonad-
otropin (Sigma-Aldrich) for 13–15 h. Uteruses were then harvested and pro-
cessed for immunohistochemistry. The experiment was repeated once with 
six mice per group.
Immunofluorescent staining. Monolayer of HUVECs was fixed in 4% 
paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated 
with a -catenin–specific antibody (BD) and Cy2-conjugated secondary 
antibody. Tumor tissue sections were incubated with antibodies against 
-catenin or CD31 (BD), followed by incubation with fluorescently con-
jugated secondary antibody. Tissues were harvested from -catenin–null 
mice were used as a negative control.
Western blot and immunoprecipitation. Cellular lysates were analyzed 
by Western blot and incubated with a specific antibody against -catenin 
(Santa  Cruz  Biotechnology,  Inc.).  For  immunoprecipitation,  cell  lysates 
were preincubated with Protein A/G agarose (Santa Cruz Biotechnology, 
Inc.). The samples were then centrifuged, and supernatants were used for 
coimmunoprecipitation  experiments.  Immunoprecipitations  were  performed 
with antibodies against either Vav1 (Santa Cruz Biotechnology, Inc.) or   
-catenin (Santa Cruz Biotechnology, Inc.) overnight, followed by incuba-
tion with Protein A/G agarose. Agarose beads were washed in cell lysis buf-
fer and boiled with gel loading buffer. Samples were then subjected to 
SDS-PAGE and Western blot analysis.
Overexpression and knockdown. For overexpression, cells were electro-
porated with plasmids using a Nucleofector device (Lonza). Knockdown of 
expression was performed by shRNA panels (Sigma-Aldrich) and transfected 
the constructs into endothelial cells by Amaxa.
Rac, RhoA, and Cdc42 activation assay. Rac1, RhoA, and Cdc42 acti-
vation kits were purchased from Chemicon. The assays were performed fol-
lowing manufacture’s instructions.
-Catenin induction in endothelial cells. HUVECs were stimulated 
with recombinant TNF, IL-1 (R and D), basic fibroblast growth factor, 
and vascular endothelial growth factor for 24 h, followed by determination 
of -catenin levels by Western blot using specific antibody. The adenoviral 
vectors directing the expression of Ang1 (AdAng1) and a mutated IB that 
can’t be phosphorylated as a NF-B inhibitor (AdIB), and control GFP 
(AdGFP)  were  described  previously  (Kobayashi  et  al.,  2006;  Kamiyama   
et al., 2006). HUVECs were infected with the viral vectors at a multiplicity 
of infection of 10.
Statistics. Results are reported as mean + SE for each group. Parametric, 
Student’s t test and nonparametric, Mann-Whitney U test, were used to   
analyze statistical differences between control and treated groups. Tests of 
hypothesis  between  groups  were  made  with  analysis  of  variance  with   
adjusted least square means. Statistical calculations were run on Prism 5 
Graph Pad. Differences were considered statistically significant if P < 0.05.
Online supplemental material. Fig. S1 shows murine 3LL tumor tissue 
sections harvested from wild-type and -catenin–null mice. Fig. S2 shows that 
knockdown of -catenin impairs angiogenic phenotype, whereas -catenin 
overexpression enhances an angiogenic phenotype in vitro. Fig. S3 shows that 
modulation of -catenin levels affect Rho GTPase activity. Fig. S4 shows 
commonly associated with disease conditions. Inflammation, 
an initial response to tissue injury and insult, often functions   
as  an  inducer  for  pathological  angiogenesis.  Consistently,   
we found that inflammatory cytokines, but not angiogenic   
factors, induce -catenin expression. In addition, the levels of 
-catenin are elevated in human lung cancer samples com-
pared with corresponding surrounding normal lung tissues, 
as inflammation is closely associated with cancer progression. 
These data may explain the association of -catenin specifically 
to pathological angiogenesis, such as with cancer. Similarly, 
elevated -catenin expression has been detected in some 
human prostate cancer samples (Lu et al., 2005).
In summary, this study identifies a new function of   
-catenin in vascular endothelium. It is conceivable to believe 
that tissue injury triggers inflammation, inflammation induces 
-catenin expression in endothelial cells, and that this ex-
pression subsequently mediates endothelial cell motility and 
angiogenesis in diseases in a gene dosage–sensitive manner. 
This notable observation of haploinsufficiency of -catenin 
in pathological angiogenesis points to a potential utility for 
targeting the gene in antiangiogenic therapy.
MATERIALS AND METHODS
Mice and cell lines. -Catenin–null mice (Israely et al., 2004) on a C57/
Bl6 background were provided by Dr. Xin Liu (University of California, Los 
Angeles, Los Angeles). -Catenin heterozygous-null mice were bred to gen-
erate wild-type littermates, heterozygous-null, and homozygous-null mice. 
All mice used in this work were housed in pathogen-free units at Vanderbilt 
University Medical Center. Animal protocols were approved by the Vander-
bilt University Institutional Animal Care and Use Committee. Age- and 
sex-matched mice were used in each study.
HUVECs were purchased from Lonza. Endothelial cells were grown on 
0.1% gelatin-coated tissue culture plates in endothelial growth medium for 
microvascular cells type two (EGM-2; Lonza). Cells between passages 3–7 
were used. Lewis lung adenocarcinoma cells were grown on tissue culture 
plates in DME supplemented with 10% FBS and 1% antibiotics. Human 
neuronal cell lines (U251MG and HT-22), human embryonic kidney epi-
thelial cells (293), and human leukocyte cell lines (THP-1 and U937) were 
grown in DME or RPMI1640 with 10% FBS. All cells were maintained in 
a humidified incubator with 5% CO2 at 37°C. Murine lung endothelial cells 
were isolated and evaluated as previously described (Kamiyama et al., 2006). 
In brief, lungs were harvested from age- and sex-matched wild-type litter-
mates, C/EBP- heterozygous, and C/EBP-–null mice, minced, and di-
gested with 0.25% Trypsin-EDTA. The single-cell suspension was cultured 
in EGM (Clonetics) for 5–6 d, followed by incubation with FITC-conju-
gated anti-mouse CD31 (BD). CD31-positive cells were sorted with a FAC-
StarPlus flow cytometer (BD). Cells used in each study were >95% pure.
In vitro angiogenic assays. Angiogenic assays were performed as previ-
ously described (Kamiyama et al., 2006). Endothelial cell migration was per-
formed in Transwell assays using 25 ng/ml VEGF (R&D Systems) as a 
chemoattractant. Vascular tubule formation was carried out in growth factor 
reduced Matrigel (BD). Cell proliferation was measured by BrDU incorpo-
ration and analyzed on a FACScan flow cytometer (BD).
In vivo angiogenesis models. Lewis lung adenocarcinoma cell tumor 
cells (5 × 105 per mouse) were injected subcutaneously into the left hind 
flank of 6-wk-old female -catenin homozygous-null, -catenin hetero-
zygous-null, or wild-type mice. Tumor growth was measured daily by cali-
per. Tumor volume was calculated as length × width2/2. At the end of the 84 -Catenin regulates pathological angiogenesis | DeBusk et al.
that tumor vascular density is reduced in heterozygous and homozygous 
-catenin–null mice. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20091097/DC1.
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